UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it has engaged RedChip Companies (“RedChip”) to lead its investor relations efforts.
“We are entering a transformative phase for ProPhase,” said Ted Karkus, CEO and Chairman of ProPhase Labs. “With the imminent commercialization of our BE-Smart™ esophageal cancer diagnostic, continued expansion of our Nebula Genomics platform, and our Crown Medical Collections initiative targeting over $50 million in near-term recoveries, we believe this is the perfect time to expand our visibility within the investment community. RedChip’s established platform and proven expertise in effectively communicating the value of emerging growth companies will help us reach a broader base of both institutional and retail investors.”
Dave Gentry, CEO of RedChip Companies, commented, “ProPhase Labs has built a compelling, diversified growth platform spanning biotechnology, genomics, and consumer health. The Company’s leadership team, headed by Ted Karkus, has a remarkable track record of execution, from monetizing legacy assets to advancing cutting-edge diagnostics like BE-Smart™ for early detection of esophageal cancer, and scaling data-driven genomics solutions through Nebula Genomics and DNA Complete®. We look forward to helping ProPhase communicate its unique story to the global investment community through our integrated investor relations and media channels.”
RedChip will employ its comprehensive, multi-channel investor relations platform, including global digital distribution, investor webinars, roadshows, and its Small Stocks, Big Money™ television program, to communicate ProPhase’s story to a wide base of institutional and retail investors.
Renmark Financial Communications will continue to host the Company’s quarterly earnings conference calls as well as retail investor virtual non-deal road shows.
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
link